durvalumab (Imfinzi) with enfortumab vedotin-ejfv (Padcev) (Imfinzi/Padcev): FDA status
Under review Under review Nov 13, 2026. Indication: Perioperative (neoadjuvant and adjuvant) treatment of cisplatin ineligible or refused muscle invasive bladder cancer. Company: AstraZeneca / Pfizer.
Regulatory history
- Nov 13, 2026: Approved. FDA approved durvalumab plus enfortumab vedotin ejfv as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for adults with MIBC ineligible for or who refused cisplatin. ascopost.com
- Nov 13, 2026: Priority review. Review was conducted under priority review and the FDA approved the application six weeks ahead of the FDA goal date. curetoday.com
Loading today's edition…